SynthesisThe British journal of dermatology2014
Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME).
Synthesis in The British journal of dermatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 3 syntheses or guidelines pooled it, 107 citations in OpenAlex.
- Interventions to reduce Staphylococcus aureus in the management of eczema.The Cochrane database of systematic reviews · 2019Pooled it
- A systematic review on the off-label use of montelukast in atopic dermatitis treatment.International journal of clinical pharmacy · 2018Pooled it
- Systematic review of atopic dermatitis disease definition in studies using routinely collected health data.The British journal of dermatology · 2018Pooled it
- Clinically Meaningful Responses to Dupilumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator's Global Assessment: A Post Hoc Analysis of a Phase 3 Trial.Acta dermato-venereologica · 2024Trial
- Dupilumab Provides Clinically Meaningful Responses in Children Aged 6-11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase III Trial.American journal of clinical dermatology · 2023Trial
- Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes.American journal of clinical dermatology · 2021Trial
- Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials.The British journal of dermatology · 2019Trial
- Trial
- Trial
- Minimum data set for treatment effectiveness in pyoderma gangrenosum (MIDSTEP): an international protocol of an e-Delphi study to develop a clinical physician-driven treatment effectiveness registry on behalf of the UPGRADE initiative.Archives of dermatological research · 2023Article
- Postinflammatory hyperpigmentation: protocol for development of a core outcome set for clinical trials.Archives of dermatological research · 2022Article
- Article
- The Unmet Needs in Atopic Dermatitis Control in Latin America: A Multidisciplinary Expert Perspective.Dermatology and therapy · 2021Review
- What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? A prospective observational study.The British journal of dermatology · 2021Observational
- Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe AD.Dermatology and therapy · 2021Article
- Measurement properties of the product of investigator's global assessment and body surface area in children and adults with atopic dermatitis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2021Article
- Counting the Burden: Atopic Dermatitis and Health-related Quality of Life.Acta dermato-venereologica · 2020Review
- Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis.The British journal of dermatology · 2019Article
- Symptoms and diagnosis of anxiety and depression in atopic dermatitis in U.S. adults.The British journal of dermatology · 2019Article
- TREatment of ATopic eczema (TREAT) Registry Taskforce: consensus on how and when to measure the core dataset for atopic eczema treatment research registries.The British journal of dermatology · 2019Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
44 authors at 20 institutions in 10 countries.
Funding
Abstract
This report provides a summary of the third meeting of the Harmonising Outcome Measures for Eczema (HOME) initiative held in San Diego, CA, U.S.A., 6-7 April 2013 (HOME III). The meeting addressed the four domains that had previously been agreed should be measured in every eczema clinical trial: clinical signs, patient-reported symptoms, long-term control and quality of life. Formal presentations and nominal group techniques were used at this working meeting, attended by 56 voting participants (31 of whom were dermatologists). Significant progress was made on the domain of clinical signs. Without reference to any named scales, it was agreed that the intensity and extent of erythema, excoriation, oedema/papulation and lichenification should be included in the core outcome measure for the scale to have content validity. The group then discussed a systematic review of all scales measuring the clinical signs of eczema and their measurement properties, followed by a consensus vote on which scale to recommend for inclusion in the core outcome set. Research into the remaining three domains was presented, followed by discussions. The symptoms group and quality of life groups need to systematically identify all available tools and rate the quality of the tools. A definition of long-term control is needed before progress can be made towards recommending a core outcome measure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.